拓新藥業(301089.SZ):子公司藥品生產許可證變更
格隆匯6月10日丨拓新藥業(301089.SZ)公佈,公司子公司新鄉製藥股份有限公司(簡稱“新鄉製藥”)近日取得了河南省藥品監督管理局頒發的《藥品生產許可證》。本次涉及變更的事項爲:同意該企業增加生產範圍:原料藥:替加氟(抗腫瘤藥)、尿嘧啶(僅限註冊申報使用)。生產車間和生產線:八車間(23號廠房B區+11號廠房E區)、原料藥(替加氟)生產線;十二車間(24號廠房B區+11號廠房C區)、原料藥(尿嘧啶)生產線。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.